News:
-
May 9, 2025Akava Therapeutics, Inc. shares recent data suggesting that AKV9 acts on a common mechanism involved in both Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS)
-
December 19, 2024Akava Therapeutics, Inc. congratulates SAB Chair Dr. Hande Ozdinler, Founder Dr. Richard B. Silverman, and Dr. William Klein on their recent grant of $7.3 million from the National Institute on Aging to investigate AKV9 in neurodegenerative diseases
-
December 17, 2024National Institute on Aging invests an additional $7.3 million into NU-9
-
August 22, 2023Akava Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for the Treatment of Amyotrophic Lateral Sclerosis
-
May 16, 2023Richard B. Silverman elected to the National Academy of Sciences
-
January 26, 2023Drug Hunter Interview
About
AKAVA Therapeutics
Our mission is to discover and develop first-in-class inhibition therapeutics addressing unmet medical needs in neurodegeneration and oncology, allowing patients to live longer with improved quality of life.
AKAVA’S lead compound, AKV9, is a protein aggregation inhibitor that was identified to be the first compound to improve the health of upper motor neurons that degenerate in motor neuron diseases, such as amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), and ALS/frontotemporal lobar degeneration (FTLD).
Science Behind the Discoveries
AKAVA Therapeutics’ programs are all based on some type of inhibition: inhibition of protein aggregation, inhibition of enzymes, and inhibition of tumor growth. We, therefore, refer to our therapeutics as inhibition therapeutics.
AKAVA’S main areas of focus are:
Pipeline
AKAVA’s pipeline is a collection of the most exciting novel compounds emerging from the Silverman Laboratory at Northwestern University. Richard B. Silverman, Ph.D. is responsible for groundbreaking research including inventing the blockbuster drug, Lyrica.
